Due to adjustments to the data sheet (EXCEL) for the 2026 audit year and feedback from developers and centres this year, changes to the specification and the OncoBox Lung 2.0 application are necessary. The changes to the data sheet are already available on the OnkoZert-Website and will not be published again here.
The cross-organ assessment of outcome quality (EQ Performance and EQ Clinical) piloted this year in OncoBox Lung 2.0 will be included in the data sheet export for lung from the 2026 audit year onwards. The data on outcome quality is generated entirely via OncoBox. The data obtained across centres will be validated in its entirety by the end of the 2026 audit year at the latest and, if necessary, used for the further development of the assessment of outcome quality. No other assessment of outcome quality is required for centres using OncoBox Lung 2.0.
All changed spreadsheets are highlighted in colour in the table of contents of the OncoBox Lung 2.0 specification. In the following table, you can check the extent to which documentation practices or the export of OncoBox Lung 2.0 have changed.
| Organ | Change / Adjustment | Task Centre | Adaption XML-interface |
|---|---|---|---|
| Lung | Histology codes: ICD-O-3 codes 8240/*, 8246/* and 8249/* no longer belong to the ‘NSCLC’ group, but form a separate group ‘carcinoids’. They are no longer counted among the NSCLC-specific indicators. | --- | --- |
| Lung | Case categories: In primary cases that have not undergone surgery, the requirement for the tumour manifestation ‘primary tumour/local recurrence’ does not apply. | --- | --- |
| Lung | Indicators 19, 21, 22, 23, 28, 31: A start date for radiotherapy or systemic therapy is required. | --- | --- |
| Lung | Indicator 21: In addition to chemotherapy in combination with other types of systemic therapy, this also includes immunotherapy/antibody therapy alone, targeted substances and hormone therapies. | --- | --- |
| Lung | Indicator 22: Only non-operated cases (NO) are counted. | --- | --- |
With the updated version of OncoBox 2.0 for the 2026 audit year (version 2.1.0), a beta version of the new OncoBox Breast 2.0 is now also available. Alongside OncoBox Lung, OncoBox Breast is the second organ to be integrated into the OncoBox 2.0 application. The beta version is primarily intended for piloting the application. For the upcoming audit year 2026, OncoBox Breast 1.0 (version N1.1.1) or the new OncoBox Breast 2.0 can be used, provided that the tumour documentation system has a verified interface. Due to the optional nature of OncoBox Breast, the data sheet can also be filled out manually. From the 2027 audit year onwards, only OncoBox Breast 2.0 will be available; OncoBox Breast 1.0 will no longer be updated for the 2027 audit year.
Application
OncoBox 2.0 Auditjahr 2026 (Version 2.1.0)
Specification
OncoBox Lunge 2.0 Spezifikation Auditjahr 2026 (Version 2.1.0)
OncoBox Brust 2.0 Spezifikation Auditjahr 2026 (Version 2.1.0-beta)